CSII: Cardiovascular Systems, Inc. Twitter

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 2, 6:26 AM Cardiovascular Systems (CSII): Q1 EPS of -$0.29 beats by $0.03. Revenue of $26.5M beats by $0.5M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, March 20, 10:21 AM Cardiovascular Systems (CSII +4%) gains this morning after pricing its 2M secondary offering at $17.60, just a mere a 1% discount to Tuesday's close. The medical device company, says it wants to use the proceeds for working capital and general corporate needs - which likely includes further funding of its Orbit II trials, a treatment therapy for severely calcified coronary lesions. The company's current float is around 21.1M shares. Comment! [Healthcare, On the Move]
Monday, March 11, 11:16 AM Cardiovascular Systems (CSII +11%) rallies after the company says Orbit II trials of its treatment therapy for patients with severely calcified coronary lesions had exceeded expectations by a significant margin. The study is reviewing the safety and effectiveness of it's orbital atherectomy technology and is the first Investigational Device Exemption study to seek approval for treating these lesions. Comment! [Healthcare, On the Move]
Thursday, January 31, 4:09 PM Despite the marketshare gains Cardiovascular Systems (CSII) has made with its Diamondback and Stealth devices for treating narrowed or blocked arteries in the leg, the real value in the company may lie in its takeout potential, says Seeking Alpha contributor Stephen Simpson. CR Bard, Cook, BSX, JNJ, MDT and ABT all have sales forces in the peripheral treatment space, making them solid candidates for a possible buyout of CSII. Comment! [Healthcare, M&A]
Thursday, January 31, 3:42 PM Cardiovascular Systems (CSII +15%) gains today after reporting a better-than-expected Q2 net loss of $0.28 per share, $0.05 wider than a year ago but nonetheless beating analyst expectations. Revenue climbed 28% Y/Y, as conversions to the company's Stealth 360 treatment for peripheral artery disease continued at a high rate, representing 93% of total device revenues for the quarter. Revenue from office-based labs also climbed at a double-digit pace. Comment! [Healthcare, On the Move, Earnings]
Thursday, January 31, 12:45 PM Midday top 10 gainers: ORCC +82%. WMS +52%. FTNT +24%. HHS +22%. EDMC +18%. BTUI +18%. JDSU +18%. PBI +17%. CSII +16%. SGI +16%.
Midday top 10 Losers: CLSN -81%. LQDT -24%. STZ -20%. NVGN -18%. FIO -16%. HALO -16%. RDEN -14%. USAK -13%. HAR -13%. JBSS -12%. Comment! [On the Move]
Thursday, January 31, 4:38 AM Cardiovascular Systems (CSII): FQ2 EPS of -$0.28 beats by $0.03. (PR) Comment! [Earnings, Breaking News, On the Move]
Thursday, May 3, 2012, 12:50 PM Cardiovascular Systems (CSII +2.5%) trades higher after William Blair upped the shares to Outperform earlier today, citing an improved growth trajectory on the back of the company's Q3 results. Comment! [Healthcare, On the Move]
Thursday, October 6, 2011, 4:19 PM Cardiovascular Systems (CSII) guides its FQ1 lower, now seeing revenue at $18.7M. The company says a shift in peripheral arterial disease procedures to physician-based labs caused hospital-based procedures and related purchases to decrease. Shares -7.9% AH. Comment! [Healthcare, On the Move]
Wednesday, February 2, 2011, 4:39 PM Cardiovascular Systems (CSII) was one of the relatively few medical device stocks to really outperform in 2010, but will a slight miss and revised guidance bring an end to the optimism? Comment! [Healthcare]

CSII Cardiovascular Systems, Inc.

CSII

Cardiovascular Systems, Inc.